BiotechTube
Molecular Partners

Molecular Partners

MOLN
Zürich, Switzerland· Est.
molecularpartners.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

MOLN · Stock Price

USD 4.10+0.00 (+0.00%)
Market Cap: $153.4M

Historical price data

Market Cap: $153.4MPipeline: 12 drugsFounded: 2004HQ: Zürich, Switzerland

Overview

Molecular Partners is a mission-driven biotech founded in 2004, focused on transforming the lives of patients with serious diseases through its innovative DARPin platform. The company has achieved clinical validation for its technology and is advancing a pipeline of next-generation oncology candidates, including tetra-specific T-cell engagers and logic-gated Switch-DARPins. Its strategy combines deep in-house R&D expertise with strategic collaborations to build a broad portfolio targeting high-unmet-need cancers.

Oncology

Technology Platform

Proprietary DARPin platform for engineering small, stable, multi-specific protein therapeutics capable of complex functions like logic-gated activation and targeted radionuclide delivery.

Pipeline

12
12 drugs in pipeline
DrugIndicationStageWatch
ensovibepCovid19Phase 2
MP0317 + Gemcitabine + Cisplatine + Durvalumab + Gemcitabine...Advanced Biliary Tract CarcinomaPhase 2
MP0250NeoplasmsPhase 1/2
[212Pb]Pb-MP0712Large Cell Neuroendocrine CarcinomaPhase 1/2
MP0533 (multispecific DARPin CD3 Engager Targeting CD33, CD1...LeukemiaPhase 1/2

Opportunities

The DARPin platform addresses major unmet needs in oncology through multi-specific targeting and conditional activation, tapping into large markets like AML and the fast-growing radiopharmaceutical sector.
Successful clinical validation could lead to lucrative partnerships or acquisition interest from larger pharma companies seeking next-generation biologic platforms.

Risk Factors

The company faces high clinical development risk with its novel platform and early-stage pipeline.
As a pre-revenue entity, it is dependent on capital markets for funding, risking shareholder dilution.
Intense competition from well-established biologics and emerging modality companies poses a significant commercial threat.

Competitive Landscape

Molecular Partners competes with large biopharma and biotechs in multi-specific engagers (e.g., Roche, Amgen) and radiopharmaceuticals (e.g., Novartis). Its differentiation lies in the DARPin scaffold's native multi-specificity, small size, and logic-gating capabilities, but it must prove these advantages clinically against entrenched and novel competitors.

More companies in Switzerland →